NasdaqGS:SNDX

Stock Analysis Report

Executive Summary

Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer.


Snowflake Analysis

Excellent balance sheet with high growth potential.

Share Price & News

How has Syndax Pharmaceuticals's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: SNDX's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

-6.2%

SNDX

4.0%

US Biotechs

9.4%

US Market


1 Year Return

36.8%

SNDX

6.1%

US Biotechs

-6.8%

US Market

Return vs Industry: SNDX exceeded the US Biotechs industry which returned 3.9% over the past year.

Return vs Market: SNDX exceeded the US Market which returned -8.1% over the past year.


Shareholder returns

SNDXIndustryMarket
7 Day-6.2%4.0%9.4%
30 Day-23.0%2.2%-3.9%
90 Day6.5%-1.5%-16.5%
1 Year36.8%36.8%6.9%6.1%-4.8%-6.8%
3 Year-16.6%-16.6%19.2%16.2%23.4%15.2%
5 Yearn/a-5.8%-10.1%41.3%25.7%

Price Volatility Vs. Market

How volatile is Syndax Pharmaceuticals's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Syndax Pharmaceuticals undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: SNDX ($9.14) is trading below our estimate of fair value ($126.09)

Significantly Below Fair Value: SNDX is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: SNDX is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: SNDX is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate SNDX's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: SNDX is overvalued based on its PB Ratio (7.9x) compared to the US Biotechs industry average (2.7x).


Next Steps

Future Growth

How is Syndax Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 6 analysts?

48.5%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: SNDX is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (1.7%).

Earnings vs Market: SNDX is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: SNDX's is expected to become profitable in the next 3 years.

Revenue vs Market: SNDX's revenue (48.1% per year) is forecast to grow faster than the US market (6.9% per year).

High Growth Revenue: SNDX's revenue (48.1% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: SNDX is forecast to be unprofitable in 3 years.


Next Steps

Past Performance

How has Syndax Pharmaceuticals performed over the past 5 years?

-1.1%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: SNDX is currently unprofitable.

Growing Profit Margin: SNDX is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: SNDX is unprofitable, and losses have increased over the past 5 years at a rate of -1.1% per year.

Accelerating Growth: Unable to compare SNDX's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: SNDX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (22%).


Return on Equity

High ROE: SNDX has a negative Return on Equity (-177.36%), as it is currently unprofitable.


Next Steps

Financial Health

How is Syndax Pharmaceuticals's financial position?


Financial Position Analysis

Short Term Liabilities: SNDX's short term assets ($62.3M) exceed its short term liabilities ($18.4M).

Long Term Liabilities: SNDX's short term assets ($62.3M) exceed its long term liabilities ($13.6M).


Debt to Equity History and Analysis

Debt Level: SNDX is debt free.

Reducing Debt: SNDX currently has no debt however we can't compare to 5 years ago as we have no data for that period.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: SNDX has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: SNDX has less than a year of cash runway if free cash flow continues to reduce at historical rates of -35% each year


Next Steps

Dividend

What is Syndax Pharmaceuticals's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate SNDX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate SNDX's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if SNDX's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if SNDX's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of SNDX's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

4.8yrs

Average management tenure


CEO

Briggs Morrison (59yo)

4.83s

Tenure

US$2,080,513

Compensation

Dr. Briggs W. Morrison, M.D. serves as the Executive Partner MPM Capital. He joined MPM in 2015. He served as the Chairman of Scientific Advisory Board at ABIONYX Pharma SA (formerly, Cerenis Therapeutics  ...


CEO Compensation Analysis

Compensation vs Market: Briggs's total compensation ($USD2.08M) is above average for companies of similar size in the US market ($USD1.45M).

Compensation vs Earnings: Briggs's compensation has increased whilst the company is unprofitable.


Leadership Team

NamePositionTenureCompensationOwnership
Briggs Morrison
CEO & Director4.83yrsUS$2.08m0.15% $401.3k
Michael Metzger
President0.75yrUS$1.52m0.058% $161.4k
Michael Meyers
Chief Medical Officer4.67yrsUS$1.05mno data
Peter Ordentlich
Co-Founder & Chief Scientific Officer14.5yrsno datano data
Richard Heyman
Co-Founderno datano datano data
Ronald Evans
Co-Founder3.75yrsno datano data
Michael Downes
Co-Founderno datano datano data
Richard Shea
CFO & Treasurer3.17yrsUS$13.00k0.024% $65.1k
Luke Albrecht
General Counsel & Corporate Secretaryno datano datano data
Edward Sausville
no datano datano data

4.8yrs

Average Tenure

60.5yo

Average Age

Experienced Management: SNDX's management team is considered experienced (4.8 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Briggs Morrison
CEO & Director4.83yrsUS$2.08m0.15% $401.3k
Michael Metzger
President0.75yrUS$1.52m0.058% $161.4k
Ronald Evans
Co-Founder3.75yrsno datano data
Jay Lichter
Observerno datano datano data
Keith Katkin
Independent Director3.08yrsUS$209.91kno data
Pierre Legault
Independent Director3.25yrsUS$223.16kno data
Dennis Podlesak
Chairman11.33yrsUS$245.16kno data
George Sledge
Member of Scientific Advisory Board3yrsUS$23.05kno data
Fabrice Egros
Independent Director6.58yrsUS$199.66kno data
Julie Brahmer
Member of Scientific Advisory Board4.33yrsno datano data

3.8yrs

Average Tenure

57.5yo

Average Age

Experienced Board: SNDX's board of directors are considered experienced (3.8 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: SNDX insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 20.2%.


Top Shareholders

Company Information

Syndax Pharmaceuticals, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Syndax Pharmaceuticals, Inc.
  • Ticker: SNDX
  • Exchange: NasdaqGS
  • Founded: 2005
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$276.401m
  • Shares outstanding: 30.24m
  • Website: https://www.syndax.com

Number of Employees


Location

  • Syndax Pharmaceuticals, Inc.
  • 35 Gatehouse Drive
  • Building D
  • Waltham
  • Massachusetts
  • 2451
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
1T3DB (Deutsche Boerse AG)YesCommon StockDEEURMar 2016
SNDXNasdaqGS (Nasdaq Global Select)YesCommon StockUSUSDMar 2016

Biography

Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. The company’s lead product candidates include entinostat, which is in Phase III clinical trials for the treatment of advanced hormone receptor positive (HR+) and human epidermal growth factor receptor 2 negative (HER2-) breast cancer; and SNDX-5613 inhibitor that targets the binding interaction of Menin with mixed lineage leukemia-rearranged and acute myeloid leukemia with a mutated nucleophosmin 1. It also develops entinostat with Keytruda (pembrolizumab) in a Phase Ib/II clinical trials for the treatment of non-small cell lung cancer and melanoma or microsatellite stable colorectal carcinoma; with Tecentriq (atezolizumab) in a Phase Ib/II clinical trials to treat patients with triple-negative breast cancer, and HR+ and HER2- metastatic breast cancer; and with Bavencio (avelumab) in a Phase Ib/II clinical trials for the treatment of ovarian cancer. In addition, the company develops SNDX-6352, a monoclonal antibody that blocks the colony stimulating factor 1 that is in Phase I dose escalation trial in patients with chronic graft versus host disease; and as a monotherapy and in combination with Imfinzi (durvalumab), which is in Phase I/Ib dose trials for the treatment of solid tumors. Syndax Pharmaceuticals, Inc. has clinical collaborations with MSD International GmbH; Genentech, Inc.; Merck KGaA and Pfizer; and AstraZeneca plc. It also has collaborative research and development agreement with National Cancer Institute; clinical trial agreement with Eastern Cooperative Oncology Group; and license agreement with Kyowa Hakko Kirin Co., Ltd. The company was founded in 2005 and is headquartered in Waltham, Massachusetts. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/04/09 01:46
End of Day Share Price2020/04/08 00:00
Earnings2019/12/31
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.